drug

plozasiran

1 story · latest Aug 4, 2026

Status: FDA approved Nov 2025 · NDA219947
Brand: Redemplo
Code: ARO-APOC3
Trials: 5 registered trials in coverage

Relationships

Developed by Arrowhead Pharmaceuticals

Timeline

Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal deal

Aug 4Quarterly updateArrowhead Pharmaceuticals plozasiran

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.